ASTRANA HEALTH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.93 USD | +3.30% |
|
+1.20% | -0.97% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 61% by 2026.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company benefits from high valuations in earnings multiples.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -0.97% | 1.77B | D+ | ||
| -14.58% | 84.68B | B- | ||
| +15.05% | 81.12B | C+ | ||
| +10.49% | 29.59B | C+ | ||
| -10.17% | 16.73B | B | ||
| -1.39% | 16.36B | A- | ||
| -31.58% | 11.77B | - | - | |
| +1.82% | 11.72B | A- | ||
| +31.86% | 11.71B | B- | ||
| -0.47% | 11.66B | A- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ASTH Stock
- Ratings Astrana Health, Inc.
